The association between immune activation and manic symptoms in patients with a depressive disorder

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Becking, K ^a   Boschloo, L ^a   Vogelzangs, N ^b   Haarman, B C M ^a   Riemersma Van Der Lek, R ^a   Penninx, B W J H ^a,b,c   Schoevers, R A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

C reactive protein; depression; immune activation; interleukin 6; manic symptoms; tumor necrosis factor alpha

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; IL6 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BIPOLAR DEPRESSION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; LIFESPAN; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MANIA; MENTAL PATIENT; PROTEIN BLOOD LEVEL; SUBSTANCE ABUSE; BIPOLAR DISORDER; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; IMMUNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; NETHERLANDS; PROSPECTIVE STUDY; SEX DIFFERENCE;

ADULT; BIPOLAR DISORDER; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER; FEMALE; HUMANS; INTERLEUKIN-6; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NETHERLANDS; PROSPECTIVE STUDIES; SEX FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886832395     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.87     Document Type: Article

References (68)

1. Maes M, Smith R, Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995; 20: 111-116. (Pubitemid 24366194)
2. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuro-psychopharmacol Biol Psychiatry 2011; 35: 664-675.
3. Calabrese JR, Skwerer RG, Barna B, Gulledge AD, Valenzuela R, Butkus A et al. Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res 1986; 17: 41-47. (Pubitemid 16212700)
4. Schiepers OJG, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 201-217. (Pubitemid 40202906)
5. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al. A metaanalysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-457.
6. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1 and IL-6: a meta-analysis. Psychosom Med 2009; 71: 171-186.
7. Hafner S, Baghai TC, Eser D, Schu le C, Rupprecht R, Bondy B. C-reactive protein is associated with polymorphisms of the angiotensin-covering enzyme in major depressed patients. J Psychiatr Res 2008; 42: 163-165. (Pubitemid 350061258)
8. Taylor SE, Lehman BJ, Kiefe CI, Seeman TE. Relationship of early life stress and psychological functioning to adult C-reactive protein in the Coronary Artery Risk Development in Young Adults Study. Biol Pscychiatry 2006; 60: 819-824. (Pubitemid 44527888)
9. Bremmer MA, Beekman ATF, Deeg DJH, BWJH Penninx, Dik MG, Hack CE et al. Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord 2008; 106: 249-255.
10. Whooley MA, Caska M, Hendrickson BE, Rourke MA, Ho J, Ali S. Depression and inflammation in patients with coronary heart disease: findings from the heart and soul study. J Psychiatr Res 2007; 62: 314-320. (Pubitemid 47444281)
11. Marques-Deak AH, Neto FL, Dominguez WV, Solis AC, Kurcgant D, Sato F et al. Cytokine profiles in women with different subtypes of major depressive disorder. J Psychiatr Res 2007; 41: 152-159. (Pubitemid 44708206)
12. Brambilla F, Monteleone P, Maj M. Interleukin-1-beta and tumor necrosis factoralpha in children with major depressive disorder or dysthymia. J Affect Disord 2004; 78: 273-277. (Pubitemid 38167748)
13. Allam E, Delacruz K, Ghoneima A, Sun J, Windsor L. Effects of tobacco on cytokine expression from human endothelial cells. Oral Dis 2012; 19: 660-665.
14. Diaz LE, Montero A, Gonzales-Gross M, Vallejo AI, Romeo J, Marcos A. Influence of alcohol consumption on immunological status: a review. Eur J Clin Nutr 2002; 56: 550-553.
15. Stewart LK, Flynn MG, Campbell WW, Craig BA, Robinson JP, Timmerman KL et al. The influence of exercise training on inflammatory cytokines and C-reactive protein. Med Sci Sports Exerc 2007; 39: 1714-1719. (Pubitemid 47511477)
16. Greenfield JR, Campbell LV. Relationship between inflammation, insulin resistance and type 2 diabetes: cause or effect Curr Diabetes Rev 2006; 2: 195-211. (Pubitemid 44082940)
17. Huth C, Heid IM, Vollmert C, Gieger C, Grallert H, Wolford JK et al. IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants data from studies. Diabetes 2006; 55: 2915-2921. (Pubitemid 44923696)
18. Miller GE, Freedland KE, Duntley S, Carney RM. Relation of depressive symptoms to C-reactive protein and pathogen burden (cytomegalovirus, herpes simplex virus, Epstein-Barr virus) in patients with earlier acute coronary syndromes. Am J Cardiol 2005; 95: 317-321. (Pubitemid 40164532)
19. Vogelzangs N, Duivis HE, Beekman ATF, Kluft C, Neuteboom J, Hoogendijk W et al. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry 2012; 2: e79.
20. Penninx BWJH, Milaneschi Y, Lamers F, Vogelzangs N. Understanding somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Medicine 2013; 11: 129.
21. Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R et al. Review: Can bipolar disorder be viewed as a multi-system inflammatory disease J Affect Disord 2012; 141: 1-10.
22. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomology, pathopyshiology, comorbidity, and treatment of bipolar disorder. J Clin Psychiatry 2009; 70: 1078-1090.
23. KimYK, JungHG, Myint AM, KimH, Park SH. Imbalance between proinflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007; 104: 91-95. (Pubitemid 350064526)
24. Zimmerman P, Bruck T, Nocon A, Pfister H, Lieb R, Wittchen H et al. Heterogeneity of DSM-IV major depressive disorder as a consequence of subtreshold bipolarity. Arch Gen Psychiatry 2009; 66: 1341-1352.
25. Angst J, Cui L, Swendsen J, Rothen S, Cravchik A, Kessler RC et al. Major depressive disorder with subtreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry 2010; 167: 1194-1201.
26. Boschloo L, Spijker AT, Hoencamp E, Kupka R, Schoevers RA, Nolen WA et al. Predictors of the onset of manic symptomatology in patients with a major depressive episode: a prospective analysis of data from the Netherlands Study of Depression and Anxiety (submitted). American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edn. American Psychiatric Association: Washington, DC, 2013.
27. Seemu ller F, Severus E, Mo ller HJ, Riedel M. Antidepressants and suicidality in younger adults; is bipolar illness the missing link Acta Psychiatr Scand 2009; 119: 166-167.
28. Angst J, Gamma A, Benazzi F, Ajdadic V, Eich D, Rossler W. Toward a re-definition of subtreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders, and hypomania. J Affect Disord 2013; 73: 133-146.
29. Lanquillon S, Krieg JC, Ling-Abu-Schach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000; 22: 370-379. (Pubitemid 30105765)
30. Eller T, Vasar V, Shlik J, Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 445-450. (Pubitemid 351178962)
31. Hovens JGFM Giltay EJ, Wiersma JE, Spinhoven P, BWJH Penninx, Zitman FG. Impact of childhood life events and trauma on the course of depressive and anxiety disorders. Acta Psychiatr Scand 2012; 126: 198-207.
32. Ghazeeri G, Abdullah L, Abbas O. Immunological differences in women compared with men: overview and contributing factors. Am J Reprod Immunol 2011; 66: 163-169.
33. Cannon JG. Cytokines in aging and muscle homeostasis. J Gerontol Biol Sci Med Sci 1995; 50 (Spec No): 120-123.
34. Bhattacharya A, Khess CR, Munda SK, Bakhla AK, Praharaj SK, Kumar M. Sex difference in symptomatology of manic episode. Compr Psychiatry 2011; 52: 288-292.
35. Chazelle E, Lemone C, Morgan K, Kelleher CC, Chastang JF, Niedhammer I. Explanations of educational differences in major depression and generalised anxiety disorder in the Irish population. J Affect Disord 2011; 134: 304-314.
36. Penninx BW, Beekman AT, Smit JH, Zitman FG, Nolen WA, Spinhoven P et al. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. Int J Methods Psychiatr Res 2008; 17: 121-140.
37. Lamers F, Hoogendoorn A, Smit J, van Dyck R, Zitman FG, Nolen WA et al. Sociodemographic and psychiatric determinants of attrition in the Netherlands Study of Depression and Anxiety (NESDA). Compr Psychiatry 2012; 53: 63-70.
38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. American Psychiatric Association: Washington, DC, 2001.
39. Wittchen HU, Robins LN, Cottler LB, Sartorius N, Burke JD, Regier D. Cross-cultural feasibility, reliability and sources of variance of the Composite International Diagnostic Interview (CIDI). The Multicentre WHO/ADAMHA field trials. Br J Psychiatry 1991; 159: 546-553658.
40. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychosometric properties. Psychol Med 1996; 28: 57-84.
41. Hirschfield RM, Holzer C, Calabrese JR, Weissman M, Reed M, Davies M et al. Validity of the mood disorder questionnaire: a general population study. Am J Psychiatry 2003; 160: 178-180. (Pubitemid 36042446)
42. Boschloo L, Nolen WA, Spijker AT, Hoencamp E, Kupka R, Penninx WB et al. The Mood Disorder Questionnaire (MDQ) for detecting (hypo)manic episodes: its validity and impact of recall bias. J Affect Disord 2013; 151: 203-208.
43. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE et al. International physical activity questionnaire; 12-country reliability and validity. Med Sci Sports Exerc 2003; 35: 1381-1395. (Pubitemid 36936159)
44. Fink LA, Bernstein D, Handelsman L, Foote J, Lovejoy M. Initial reliability and validity of the childhood trauma interview: a new multidimensional measure of childhood interpersonal trauma. Am J Psychiatry 1995; 152: 1329-1335.
45. Vogelzangs N, Seldenrijk A, Beekman AT, van Hout HP, de Jonge P, Penninx BW. Cardiovascular disease in persons with depressive and anxiety disorders. J Affect Disord 2010; 125: 241-248.
46. WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical Classification. World Health Organization: Geneva, 2007.
47. Padmos RC, Hilligers MH, Knijf EM, Vonk R, Bouvy A, Staal FJ et al. A discriminating messenger RNA signature for bipolar disorder formed by aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry 2008; 65: 395-407. (Pubitemid 351519889)
48. Goldstein BI, Collinger KA, Lotrich F, Marsland AL, Gill MK, Axelson DA et al. Preliminary findings regarding proinflammatory markers and brain-derived neutrophic factor among adolescents with bipolar spectrum disorders. J Child Adolesc Psychopharmacol 2011; 21: 479-484.
49. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuro-psychopharmacol Biol Psychiatry 2007; 31: 952-955. (Pubitemid 46660310)
50. Cunha AB, Andreazza AC, Gomes FA, Frey BN, da Silveira LE, Concalves CA et al. Investigation of serumhigh-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2008; 248: 300-304.
51. Kushner I, Jiang SL, Zhang D, Lozanski G, Samols D. Do post-transcriptional mechanisms participate in induction of C-reactive protein and serum amyloid A by IL-6 and IL-1 Ann NY Acad Sci 1995; 762: 102-107.
52. Wadee AA, Kuschke RH, Wood LA, Berk M, Ichim L, Maes M. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol 2002; 17: 175-179. (Pubitemid 34678878)
53. Su SC, Sun MT, Wen MJ, Lin CJ, Chen YC, Hung YJ. Brain-derived neutrophic factor, adiponectin, and proinflammatory markers in various subtypes of depression in young men. Int J Psychiatry Med 2011; 42: 211-226.
54. Mullington JM, Haack M, Toth M, Serrador JM, Meier-Ewert HK. Cardiovascular, inflammatory and metabolic consequences of sleep deprivation. Progr Carciovasc Dis 2009; 51: 294-302.
55. Harvey AG. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony and regulation. Am J Psychiatry 2008; 165: 820-829. (Pubitemid 351948714)
56. Bauer M, Grof P, Rasgon N, Bschor T, Glenn T, Whybrow PC. Temporal relation between sleep and mood in patients with bipolar disorder. Bipolar Disord 2006; 8: 160-167. (Pubitemid 44026768)
57. Leibenluft E, Albert PS, Rosenthal NE, Wehr TA. Relationship between sleep and mood in patients with rapid-cycling bipolar disorder. Psychiatry Res 1996; 63: 161-168. (Pubitemid 26276607)
58. Barbini B, Bertelli S, Colombo C, Smeraldi E. Sleep loss, a possible factor in augmenting manic episode. Psychiatry Res 1996; 65: 121-125. (Pubitemid 27050695)
59. Schrocksnadel K, Wirleitner B, Winkler C, Fusch D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 2006; 364: 82-90. (Pubitemid 43120630)
60. Heyes MP, Saito K, Markey SP. Human macrophages convert L-tryptophan into the neurotoxin quinolic acid. Biochem J 1992; 293: 633-635.
61. Mellor AL, Munn DH. Tryptophan catabolism a T-cell tolerance: immunosuppression by starvation Immunol Today 1999; 20: 469-473. (Pubitemid 29476077)
62. Muller N, Schwartz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Pscychiatry 2007; 12: 988-1000. (Pubitemid 350006207)
63. Miller CL, Llenos JC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulated cortex from individuals with schizophrenia and bipolar disorder. Brain Res 2006; 1073-1074: 25-57.
64. Myint AM, Kim YK, Verkerk R, Park SH, Scharpe S, Steinbusch HW et al. Tryptophan breakdown pathway in bipolar mania. J Affect Disord 2007; 102: 65-72. (Pubitemid 47042175)
65. Hirschfeld RM. Bipolar depression: the real challenge. Eur Neuropsychopharmacol 2004; 14(Suppl 2): S83-S88. (Pubitemid 38610216)
66. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF et al. A randomized controlled trial of the tumor necrosis factor antagonist Infliximab for treatment-resistant depression. Arch Gen Psychiatry 2012; 70: 31-41.
67. Languillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacol 2000; 22: 370-379. (Pubitemid 30105765)
68. Eller T, Vasar V, Shilk J, Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 445-450. (Pubitemid 351178962)